147 related articles for article (PubMed ID: 36265120)
1. The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
Paudel R; Madan R; Qi J; Ferrante S; Cher ML; Lane BR; George AK; Semerjian A; Ginsburg KB
J Urol; 2023 Jan; 209(1):170-179. PubMed ID: 36265120
[TBL] [Abstract][Full Text] [Related]
2. Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?
Ahmad AE; Richard PO; Leão R; Hajiha M; Martin LJ; Komisarenko M; Grewal R; Goldberg H; Salem S; Jain K; Oliaei A; Horyn I; Timilshina N; Zlotta A; Hamilton R; Kulkarni G; Fleshner N; Alibhaic SMH; Finelli A
J Urol; 2020 Sep; 204(3):476-482. PubMed ID: 32259466
[TBL] [Abstract][Full Text] [Related]
3. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
5. Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
Arcot R; Cher ML; Qi J; Linsell SM; Dunn RL; George AK; Montie JE; Ginsburg KB;
Prostate; 2022 Feb; 82(3):323-329. PubMed ID: 34855239
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed Prostatectomy.
Auffenberg GB; Linsell S; Dhir A; Myers SN; Rosenberg B; Miller DC;
J Urol; 2016 Nov; 196(5):1415-1421. PubMed ID: 27256204
[TBL] [Abstract][Full Text] [Related]
7. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
[TBL] [Abstract][Full Text] [Related]
8. Delaying Surgery in Favorable-Risk Prostate Cancer Patients: An NCDB Analysis of Oncologic Outcomes.
Luu J; Antar RM; Farag C; Simmens S; Whalen MJ
Clin Genitourin Cancer; 2024 Jun; 22(3):102092. PubMed ID: 38697001
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
[TBL] [Abstract][Full Text] [Related]
11. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
Patel HD; Tosoian JJ; Carter HB; Epstein JI
JAMA Oncol; 2018 Jan; 4(1):89-92. PubMed ID: 28715578
[TBL] [Abstract][Full Text] [Related]
12. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
[TBL] [Abstract][Full Text] [Related]
13. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
[TBL] [Abstract][Full Text] [Related]
14. The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide.
Vince RA; Sun Y; Mahal B; Ginsburg K; George A; Cher M; Lane B; Sarle R; Morgan TM; Spratt DE
Eur Urol; 2023 Apr; 83(4):307-310. PubMed ID: 35688664
[TBL] [Abstract][Full Text] [Related]
15. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
Nyame YA; Wilkins L; Greene DJ; Ganesan V; Dai C; Almassi N; Stephenson AJ; Gong M; Berglund R; Klein EA
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):617-623. PubMed ID: 30996285
[TBL] [Abstract][Full Text] [Related]
16. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
[TBL] [Abstract][Full Text] [Related]
18. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
Baraban E; Erak E; Fatima A; Akbari A; Zhao J; Fletcher SA; Bhanji Y; de la Calle CM; Mamawala M; Landis P; Macura KJ; Pavlovich CP; Epstein JI
J Urol; 2023 Jul; 210(1):99-107. PubMed ID: 37042826
[TBL] [Abstract][Full Text] [Related]
19. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
20. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
